Hilton Worldwide Indefinite-Lived Research and Development Assets decreased by 0.2% to $5.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.3%, from $5.00B to $5.01B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.90B | $4.89B | $4.88B | $4.88B | $4.85B | $4.81B | $4.84B | $4.84B | $4.84B | $4.83B | $4.85B | $4.83B | $4.99B | $5.02B | $4.99B | $5.00B | $5.03B | $5.02B | $5.02B | $5.01B |
| QoQ Change | — | -0.2% | -0.1% | -0.2% | -0.6% | -0.7% | +0.5% | +0.0% | +0.0% | -0.2% | +0.3% | -0.3% | +3.4% | +0.4% | -0.5% | +0.2% | +0.5% | -0.1% | +0.0% | -0.2% |
| YoY Change | — | — | — | — | -1.1% | -1.6% | -0.9% | -0.7% | -0.1% | +0.4% | +0.1% | -0.2% | +3.1% | +3.8% | +3.0% | +3.5% | +0.7% | +0.1% | +0.7% | +0.3% |